Use of a Medical Food in Adults Undergoing Surgery
Observation of the Use of a Medical Food in Older Adults Undergoing Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- ClinOhio Research Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is scheduled to have non-melanoma skin cancer on either the head, leg, trunk and arm removed with final wound size of 1.0 to < 5.0 cm in diameter or with 1.0 < 5.0 cm long axis if not circular that will be healed by secondary intent
- Participant has an acceptable state of health and nutrition
- Participant agrees not to begin taking any new medications, dietary supplements, or alternative therapies during the study period
- Participant is interested in participating in the study, willing to comply with the study protocol, and willing to consume two servings of drink mix per day according to the protocol
- Participant has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability (HIPAA) authorization prior to any study participation
Exclusion Criteria:
- Participant has a disease or condition that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the participant with study visits/procedures
- Participant has type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
- Participant has known immunosuppression
- Participant has platelet or coagulation disorders
- Therapy with another investigational agent within 30 days of Visit 1 that has not been approved
- Systemic infection at the time of enrollment in the study
- Currently receiving or have received recombinant human platelet-derived growth factor or similar therapies, or other bioengineered tissue therapy within the previous 4 weeks
- Participant has an allergy or intolerance to any ingredient in the study product
- Participant is taking nutritional supplement(s)/capsules/formulas for wound healing and is unwilling to discontinue therapy for the duration of the study
- Participation in another clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental Product
Drink mix powder
|
2 sachets per day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Product Compliance
Time Frame: Study Day 1 to Study Day 30
|
Percent of required study product intake from subject completed intake questionnaire
|
Study Day 1 to Study Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Investigator Wound Assessment
Time Frame: Study Day 1 to Study Day 30
|
Percent of patients with complete wound healing based on physician assessment
|
Study Day 1 to Study Day 30
|
|
Participant Wound Assessment Questionnaire
Time Frame: Study Day 14 and Study Day 30
|
Participant completed 4 questions related to wound healing experience; 3 Likert-type questions scaled from 1-10 in negative direction; 1 dichotomous scale question
|
Study Day 14 and Study Day 30
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Product Evaluation Questionnaire
Time Frame: Study Day 30/Exit
|
Participant completed questionnaire; 4 Likert-type questions scaled from 1 - 9 in the negative direction; 2 Likert-type questions scaled from 1 - 5 in the negative direction
|
Study Day 30/Exit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jeffrey Nelson, PhD, Abbott Nutrition
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BL42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Compliance, Patient
-
NCT03373227CompletedCompliance, Patient | Graft Failure | Heart Transplant Rejection
-
NCT04249518UnknownPatient Engagement | Patient Empowerment | Patient Compliance
-
NCT04243980UnknownPatient Satisfaction | Patient Compliance
-
NCT07607145Not yet recruitingHand Hygiene Compliance
-
NCT02669355CompletedPatient Compliance | Physician-Patient Relations
-
NCT06023615Active, not recruitingMedication Adherence | Medication Compliance
-
NCT06411847RecruitingCompliance, Patient
-
NCT03124667CompletedPatient Compliance
-
NCT04250987Completed
Clinical Trials on Experimental Product
-
NCT05301556CompletedGastrointestinal Cancer
-
NCT05204823CompletedGlycemic Index | Cognitive Performance
-
NCT05597189CompletedBack Pain | Supplementation
-
NCT06154616Completed
-
NCT05750342Completed
-
NCT04749017Completed
-
NCT07426406RecruitingGastrointestinal Tolerance
-
NCT04800211Completed
-
NCT03723681Completed